항당뇨병제 시장 조사 보고서 : 산업 분석, 규모, 점유율, 성장, 동향, 예측(2024-2032년)

The global demand for Antidiabetics Market is presumed to reach the market size of nearly USD 261.23 Billion by 2032 from USD 87.8 Billion in 2023 with a CAGR of 12.88% under the study period 2024-2032.

Antidiabetic drugs are medicines introduced to stabilise and control blood glucose levels in people suffering from diabetes. Antidiabetic drugs are mainly used to manage diabetes and aid diabetic patients in maintaining their condition and lowering their risk of developing diabetes. Antidiabetic drugs include insulin, pramlintide, byetta,victoza and oral hypoglycemics (tablets).

MARKET DYNAMICS

The growing rates of diabetics and rising healthcare expenditure are the fundamental factors that are spurring the growth of the global antidiabetics market. Also, the global prevalence of obesity is expected to serve the antidiabetics market as a driver. Moreover, various significant participants are adopting business growth strategies such as R&D investments and product launches, boosting the antidiabetics market's growth. Furthermore, several campaigns for awareness and education programs created by associations and diabetes societies to raise awareness levels and provide information about diabetes control will stimulate further growth. However, the cost of insulin may limit antidiabetic market growth to some extent.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of Antidiabetics. The growth and trends of Antidiabetics industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the Antidiabetics market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Drug Class Scope

• Insulin (Long-acting Insulin, Premix Insulin, Fast-acting Insulin, Human Insulin)
• GLP-1 Receptor Agonists
• DPP- 4 Inhibitors
• SGLT2 Inhibitors
• Others

By Diabetes Type Scope

• Type 1
• Type 2

By Route of Administration Scope

• Oral
• Subcutaneous
• Intravenous

By Distribution Channel Scope

• Online pharmacies
• Hospital Pharmacies
• Retail pharmacies

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Antidiabetics market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Antidiabetics market include AstraZeneca Plc, Bayer AG, Takeda Pharmaceutical Company Limited, Eli Lilly And Company, Boehringer Ingelheim, Bristol-Myers Squibb, Pfizer Inc., Johnson & Johnson Services Inc., Merck & Co. Inc, Novartis AG. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1. PREFACE

• 1.1. Report Description
  • 1.1.1 Objective
  • 1.1.2 Target Audience
  • 1.1.3 Unique Selling Proposition (USP) & offerings
• 1.2. Research Scope
• 1.3. Research Methodology
  • 1.3.1 Market Research Process
  • 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

• 2.1. Highlights of Market
• 2.2. Global Market Snapshot

3. ANTIDIABETICS - INDUSTRY ANALYSIS

• 3.1. Introduction - Market Dynamics
• 3.2. Market Drivers
• 3.3. Market Restraints
• 3.4. Opportunities
• 3.5. Industry Trends
• 3.6. Porter's Five Force Analysis
• 3.7. Market Attractiveness Analysis
  • 3.7.1 Market Attractiveness Analysis By Drug Class Scope
  • 3.7.2 Market Attractiveness Analysis By Diabetes Type Scope
  • 3.7.3 Market Attractiveness Analysis By Route of Administration Scope
  • 3.7.4 Market Attractiveness Analysis By Distribution Channel Scope
  • 3.7.5 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

• 4.1. Value Chain Analysis
• 4.2. Raw Material Analysis
  • 4.2.1 List of Raw Materials
  • 4.2.2 Raw Material Manufactures List
  • 4.2.3 Price Trend of Key Raw Materials
• 4.3. List of Potential Buyers
• 4.4. Marketing Channel
  • 4.4.1 Direct Marketing
  • 4.4.2 Indirect Marketing
  • 4.4.3 Marketing Channel Development Trend

5. GLOBAL ANTIDIABETICS MARKET ANALYSIS BY DRUG CLASS SCOPE

• 5.1. Overview By Drug Class Scope
• 5.2. Historical and Forecast Data Analysis By Drug Class Scope
• 5.3. Insulin (Long-acting Insulin, Premix Insulin, Fast-acting Insulin, Human Insulin) Historic and Forecast Sales By Regions
• 5.4. GLP-1 Receptor Agonists Historic and Forecast Sales By Regions
• 5.5. DPP- 4 Inhibitors Historic and Forecast Sales By Regions
• 5.6. SGLT2 Inhibitors Historic and Forecast Sales By Regions
• 5.7. Others Historic and Forecast Sales By Regions

6. GLOBAL ANTIDIABETICS MARKET ANALYSIS BY DIABETES TYPE SCOPE

• 6.1. Overview By Diabetes Type Scope
• 6.2. Historical and Forecast Data Analysis By Diabetes Type Scope
• 6.3. Type 1 Historic and Forecast Sales By Regions
• 6.4. Type 2 Historic and Forecast Sales By Regions

7. GLOBAL ANTIDIABETICS MARKET ANALYSIS BY ROUTE OF ADMINISTRATION SCOPE

• 7.1. Overview By Route of Administration Scope
• 7.2. Historical and Forecast Data Analysis By Route of Administration Scope
• 7.3. Oral Historic and Forecast Sales By Regions
• 7.4. Subcutaneous Historic and Forecast Sales By Regions
• 7.5. Intravenous Historic and Forecast Sales By Regions

8. GLOBAL ANTIDIABETICS MARKET ANALYSIS BY DISTRIBUTION CHANNEL SCOPE

• 8.1. Overview By Distribution Channel Scope
• 8.2. Historical and Forecast Data Analysis By Distribution Channel Scope
• 8.3. Online pharmacies Historic and Forecast Sales By Regions
• 8.4. Hospital Pharmacies Historic and Forecast Sales By Regions
• 8.5. Retail pharmacies Historic and Forecast Sales By Regions

9. GLOBAL ANTIDIABETICS MARKET ANALYSIS BY GEOGRAPHY

• 9.1. Regional Outlook
• 9.2. Introduction
• 9.3. North America Sales Analysis
  • 9.3.1 Overview, Historic and Forecast Data Sales Analysis
  • 9.3.2 North America By Segment Sales Analysis
  • 9.3.3 North America By Country Sales Analysis
  • 9.3.4 United States Sales Analysis
  • 9.3.5 Canada Sales Analysis
  • 9.3.6 Mexico Sales Analysis
• 9.4. Europe Sales Analysis
  • 9.4.1 Overview, Historic and Forecast Data Sales Analysis
  • 9.4.2 Europe By Segment Sales Analysis
  • 9.4.3 Europe By Country Sales Analysis
  • 9.4.4 United Kingdom Sales Analysis
  • 9.4.5 France Sales Analysis
  • 9.4.6 Germany Sales Analysis
  • 9.4.7 Italy Sales Analysis
  • 9.4.8 Russia Sales Analysis
  • 9.4.9 Rest Of Europe Sales Analysis
• 9.5. Asia Pacific Sales Analysis
  • 9.5.1 Overview, Historic and Forecast Data Sales Analysis
  • 9.5.2 Asia Pacific By Segment Sales Analysis
  • 9.5.3 Asia Pacific By Country Sales Analysis
  • 9.5.4 China Sales Analysis
  • 9.5.5 India Sales Analysis
  • 9.5.6 Japan Sales Analysis
  • 9.5.7 South Korea Sales Analysis
  • 9.5.8 Australia Sales Analysis
  • 9.5.9 South East Asia Sales Analysis
  • 9.5.10 Rest Of Asia Pacific Sales Analysis
• 9.6. Latin America Sales Analysis
  • 9.6.1 Overview, Historic and Forecast Data Sales Analysis
  • 9.6.2 Latin America By Segment Sales Analysis
  • 9.6.3 Latin America By Country Sales Analysis
  • 9.6.4 Brazil Sales Analysis
  • 9.6.5 Argentina Sales Analysis
  • 9.6.6 Peru Sales Analysis
  • 9.6.7 Chile Sales Analysis
  • 9.6.8 Rest of Latin America Sales Analysis
• 9.7. Middle East & Africa Sales Analysis
  • 9.7.1 Overview, Historic and Forecast Data Sales Analysis
  • 9.7.2 Middle East & Africa By Segment Sales Analysis
  • 9.7.3 Middle East & Africa By Country Sales Analysis
  • 9.7.4 Saudi Arabia Sales Analysis
  • 9.7.5 UAE Sales Analysis
  • 9.7.6 Israel Sales Analysis
  • 9.7.7 South Africa Sales Analysis
  • 9.7.8 Rest Of Middle East And Africa Sales Analysis

10. COMPETITIVE LANDSCAPE OF THE ANTIDIABETICS COMPANIES

• 10.1. Antidiabetics Market Competition
• 10.2. Partnership/Collaboration/Agreement
• 10.3. Merger And Acquisitions
• 10.4. New Product Launch
• 10.5. Other Developments

11. COMPANY PROFILES OF ANTIDIABETICS INDUSTRY

• 11.1. Top Companies Market Share Analysis
• 11.2. Market Concentration Rate
• 11.3. AstraZeneca Plc
  • 11.3.1 Company Overview
  • 11.3.2 Company Revenue
  • 11.3.3 Products
  • 11.3.4 Recent Developments
• 11.4. Bayer AG
  • 11.4.1 Company Overview
  • 11.4.2 Company Revenue
  • 11.4.3 Products
  • 11.4.4 Recent Developments
• 11.5. Takeda Pharmaceutical Company Limited
  • 11.5.1 Company Overview
  • 11.5.2 Company Revenue
  • 11.5.3 Products
  • 11.5.4 Recent Developments
• 11.6. Eli Lilly And Company
  • 11.6.1 Company Overview
  • 11.6.2 Company Revenue
  • 11.6.3 Products
  • 11.6.4 Recent Developments
• 11.7. Boehringer Ingelheim
  • 11.7.1 Company Overview
  • 11.7.2 Company Revenue
  • 11.7.3 Products
  • 11.7.4 Recent Developments
• 11.8. Bristol-Myers Squibb
  • 11.8.1 Company Overview
  • 11.8.2 Company Revenue
  • 11.8.3 Products
  • 11.8.4 Recent Developments
• 11.9. Pfizer Inc.
  • 11.9.1 Company Overview
  • 11.9.2 Company Revenue
  • 11.9.3 Products
  • 11.9.4 Recent Developments
• 11.10. Johnson & Johnson Services Inc.
  • 11.10.1 Company Overview
  • 11.10.2 Company Revenue
  • 11.10.3 Products
  • 11.10.4 Recent Developments
• 11.11. Merck & Co. Inc
  • 11.11.1 Company Overview
  • 11.11.2 Company Revenue
  • 11.11.3 Products
  • 11.11.4 Recent Developments
• 11.12. Novartis AG
  • 11.12.1 Company Overview
  • 11.12.2 Company Revenue
  • 11.12.3 Products
  • 11.12.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies